Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis
Sojin Lee, … , Allan Tsung, H. Henry Dong
Sojin Lee, … , Allan Tsung, H. Henry Dong
Published June 14, 2022
Citation Information: J Clin Invest. 2022;132(14):e154333. https://doi.org/10.1172/JCI154333.
View: Text | PDF
Research Article Endocrinology Metabolism

Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis

  • Text
  • PDF
Abstract

Hepatic inflammation is culpable for the evolution of asymptomatic steatosis to nonalcoholic steatohepatitis (NASH). Hepatic inflammation results from abnormal macrophage activation. We found that FoxO1 links overnutrition to hepatic inflammation by regulating macrophage polarization and activation. FoxO1 was upregulated in hepatic macrophages, correlating with hepatic inflammation, steatosis, and fibrosis in mice and patients with NASH. Myeloid cell conditional FoxO1 knockout skewed macrophage polarization from proinflammatory M1 to the antiinflammatory M2 phenotype, accompanied by a reduction in macrophage infiltration in liver. These effects mitigated overnutrition-induced hepatic inflammation and insulin resistance, contributing to improved hepatic metabolism and increased energy expenditure in myeloid cell FoxO1–knockout mice on a high-fat diet. When fed a NASH-inducing diet, myeloid cell FoxO1–knockout mice were protected from developing NASH, culminating in a reduction in hepatic inflammation, steatosis, and fibrosis. Mechanistically, FoxO1 counteracts Stat6 to skew macrophage polarization from M2 toward the M1 signature to perpetuate hepatic inflammation in NASH. FoxO1 appears to be a pivotal mediator of macrophage activation in response to overnutrition and a therapeutic target for ameliorating hepatic inflammation to stem the disease progression from benign steatosis to NASH.

Authors

Sojin Lee, Taofeek O. Usman, Jun Yamauchi, Goma Chhetri, Xingchun Wang, Gina M. Coudriet, Cuiling Zhu, Jingyang Gao, Riley McConnell, Kyler Krantz, Dhivyaa Rajasundaram, Sucha Singh, Jon Piganelli, Alina Ostrowska, Alejandro Soto-Gutierrez, Satdarshan P. Monga, Aatur D. Singhi, Radhika Muzumdar, Allan Tsung, H. Henry Dong

×

Figure 2

Myeloid FoxO1 depletion protects against HFD-induced insulin resistance and glucose intolerance.

Options: View larger image (or click on image) Download as PowerPoint
Myeloid FoxO1 depletion protects against HFD-induced insulin resistance ...
MøFoxO1-KO and WT littermates (male, 8 weeks old) were fed HFD for 34 weeks. (A) Body weight. (B) Glucose tolerance test. (C) Basal and glucose-stimulated insulin secretion. (D) Insulin tolerance test. (E) HOMA-IR. (F) Plasma TG levels. (G) Plasma cholesterol levels. (H) Anti-Akt1, anti–p-Akt1 (S473), and anti-actin immunoblots. WT and MøFoxO1-KO mice were fasted for 16 hours after 3 months of HFD feeding, followed by intravenous injection of insulin (5 IU/kg) or saline. Mice were euthanized 5 minutes after insulin or saline injection. Liver tissues were procured for the preparation of total liver proteins. Aliquots of liver proteins (15 μg) were analyzed by anti-Akt1 (or anti-FoxO1) and anti-p-Akt1 (or anti-p-FoxO1) immunoblotting, using anti-actin immunoblot as control. (I) Ratio of p-Akt1/Akt1 protein levels, as quantified from H. (J) Anti-FoxO1 and anti–p-FoxO1 (S253) immunoblot. (K) Ratio of p-FoxO1/FoxO1, as quantified from J. Data are expressed as mean ± SEM (n = 8–12). Statistical analysis in A, B, and D–G was performed using a 2-tailed, unpaired t test, and in C, I, and K using 1-way ANOVA with Tukey’s multiple-comparison test. *P < 0.05; ***P < 0.001. NS, not significant.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts